Corporate Report: Medexus Pharmaceuticals Inc. (MDP.TO)
Medexus Pharmaceuticals Inc. (MDP.TO) closed its most recent trading session flat, with no change in price during the 24‑hour period ending at 05:50 PM Central Europe on Thursday, 22 November 2026. The share price remains at approximately CAD 4.96 on the Toronto Stock Exchange, where it is listed under the ticker MDP.
Market Metrics
- Current market capitalization: CAD 154 million
- Shares outstanding: 31.4 million
- Trading volume (last 24 h): CAD 82.3 k worth of shares exchanged
- 52‑week high: CAD 5.50 (08 December 2026)
- 52‑week low: CAD 2.51 (20 November 2025)
- Simple moving average (200 days): CAD 4.83
- Change since last month‑end: –4.05 %
The flat performance reflects a period of consolidation after a modest decline over the past month, while the stock’s volatility remains within the range typical for mid‑cap pharmaceutical companies.
Industry Context: Peer Movements
The performance of Medexus’ peer companies provides a broader view of the sector’s dynamics in the last 24 hours:
| Company | Ticker | % Move | Current Price | Market Cap | Key Update |
|---|---|---|---|---|---|
| Selkirk Copper Mines | SCMI.V | +2.23 % | CAD 1.05 | CAD 179.3 M | Phase 2 drilling at Minto Project produced high‑grade intercepts, strengthening confidence in mineral continuity and supporting a 13‑year mine life projection. |
| Airboss Of America | BOS.TO | –0.15 % | CAD 6.51 | CAD 182 M | Upcoming third‑quarter 2026 results to be released on 4 November; earnings call scheduled 5 November at 9 AM ET. |
| Southern Silver Exploration | SSV.V | –1.14 % | CAD 0.41 | CAD 182.7 M | Ongoing drilling at Cerro Las Minitas; preparing updated resource estimate and preliminary economic assessment. |
| Beyond Oil | BOIL.TO | +0.45 % | CAD 2.30 | CAD 182.7 M | Initiated operations in Romania via a distribution partnership with Grupo General ID; first container order placed, marking a strategic expansion into the European HoReCa sector. |
| Organigram Global | OGI.TO | –0.75 % | CAD 1.32 | CAD 184.7 M | P/E ratio of 2.07; no significant news released during the period. |
Company Overview
Medexus Pharmaceuticals Inc. specializes in therapeutic areas that include rheumatology, auto‑immune disease, specialty oncology, and pediatrics. Headquartered in Verdun, the company operates across North America and Canada, focusing on innovative drug development and commercialization. Medexus is listed on the Toronto Stock Exchange and its shares are actively traded under the ticker MDP.
For further information, investors can visit the company’s website at www.medexus.com .
